The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Open accessAbstract
BACKGROUND: FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadustat, CDAN name: ), a HIF-PHI, in patients with anemia of chronic kidney disease (CKD), both patients who were dialysis-dependent (DD) and patients who were not dialysis-dependent (NDD). METHODS: In the NDD study, 91 participants were randomized to low (1.1-1.75 mg/kg) or high (1.50-2.25 mg/kg) FG-4592 starting doses or to placebo. In the DD study, 87 were enrolled to low (1.1-1.8 mg/kg), medium (1.5-2.3 mg/kg) and high (1.7-2.3 mg/kg) starting FG-4592 doses or to continuation of epoetin alfa. In both studies, only oral iron supplementation was allowed. RESULTS: In the NDD study, hemoglobin (Hb) increase ≥1 g/dL from baseline was achieved in 80.0% of subjects in the low-dose cohort and 87.1% in the high-dose cohort, versus 23.3% in the placebo arm (P < 0.0001, both). In the DD study, 59.1%, 88.9% (P = 0.008) and 100% (P = 0.0003) of the low-, medium- and high-dose subjects maintained their Hb levels after 5- and 6-weeks versus 50% of the epoetin alfa-treated subjects. In both studies, significant reductions in cholesterol were noted in FG-4592-treated subjects, with stability or increases in serum iron, total iron-binding capacity (TIBC) and transferrin (without intravenous iron administration). In the NDD study, hepcidin levels were significantly reduced across all FG-4592-treated arms as compared with no change in the placebo arm. In the DD study, hepcidin levels were also reduced in a statistically significant dose-dependent manner in the highest dose group as compared with the epoetin alfa-treated group. Adverse events were similar for FG-4592-treated and control subjects. CONCLUSIONS: FG-4592 may prove an effective alternative for managing anemia of CKD. It is currently being investigated in a pivotal global Phase 3 program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Self-citationBabitt, J. L., & Lin, H. Y. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111078 · Cited by 1,041
Self-citationEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
Bernhardt, W. M., Wiesener, M. S., Scigalla, P., Chou, J., Schmieder, R. E., Günzler, V., & Eckardt, K.-U. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010116 · Cited by 340
Anaemia in kidney disease: harnessing hypoxia responses for therapy
Koury, M. J., & Haase, V. H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.82 · Cited by 313
Role of the hypoxia inducible factors HIF in iron metabolism
Peyssonnaux, C., Nizet, V., & Johnson, R. S. (2008) · Cell Cycle · doi:10.4161/cc.7.1.5145 · Cited by 217
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
Besarab, A., Frinak, S., & Yee, J. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.007 · Cited by 34
Self-citation
Cited by
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
Chen, N., Hao, C., Liu, B.-C., Lin, H., Wang, C., Xing, C., Liang, X., Jiang, G., Liu, Z., Li, X., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901713 · Cited by 621
Self-citationGanz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Self-citationMechanisms of hypoxia signalling: new implications for nephrology
Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Metadata
- Authors
- Chen, N., Qian, J., Chen, J., Yu, X., Mei, C., Hao, C., Jiang, G., Lin, H., Zhang, X., Zuo, L., He, Q., Fu, P., Li, X., Ni, D., Hemmerich, S., Liu, C., Szczech, L., Besarab, A., Neff, T. B., Peony Yu, K.-H., & Valone, F. H.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-27
- Volume
- 32
- Issue
- 8
- Pages
- 1373-1386
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2599499085
- Cited by
- 205
- References
- 10
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. https://app.cochat.ai/papers/10.1093/ndt/gfx011
- The paper
- Chen, N., Qian, J., Chen, J., Yu, X., Mei, C., Hao, C., Jiang, G., Lin, H., Zhang, X., Zuo, L., He, Q., Fu, P., Li, X., Ni, D., Hemmerich, S., Liu, C., Szczech, L., Besarab, A., Neff, T. B., . . . Valone, F. H. (2017). Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfx011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.